Literature DB >> 8972226

Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.

D M Bortner1, M P Rosenberg.   

Abstract

Deregulated expression of several cell cycle regulatory genes has been demonstrated to be associated with cancer. In particular, a strong correlation has been established between inappropriate cyclin E expression and human breast cancer. To determine the ability of cyclin E to play a causative role in mammary tumorigenesis, regulatory sequences from the ovine beta-lactoglobulin gene were utilized to specifically target expression of human cyclin E to the mammary glands of pregnant and lactating mice. Lactating mammary glands of transgenic mice expressing cyclin E contained areas of hyperplasia, primarily papillary projections of hyperplastic cells, which were rarely observed in lactating glands of control mice. Over 10% of female cyclin E transgenic mice have developed mammary carcinomas, with latencies ranging from 8 to 13 months. Tumor analysis revealed the presence of transgene-specific cyclin E RNA and protein, as well as cyclin E- and cdk2-associated kinase activity, suggesting that cyclin E is likely a contributing component of tumorigenic progression in this model system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8972226      PMCID: PMC231770          DOI: 10.1128/MCB.17.1.453

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

Review 1.  Inhibitors of mammalian G1 cyclin-dependent kinases.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

Review 2.  Principles of CDK regulation.

Authors:  D O Morgan
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

3.  Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E.

Authors:  A Wimmel; F C Lucibello; A Sewing; S Adolph; R Müller
Journal:  Oncogene       Date:  1994-03       Impact factor: 9.867

Review 4.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

5.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

6.  The function(s) of CAK, the p34cdc2-activating kinase.

Authors:  M J Solomon
Journal:  Trends Biochem Sci       Date:  1994-11       Impact factor: 13.807

7.  Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.

Authors:  J Lukas; J Bartkova; M Rohde; M Strauss; J Bartek
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

8.  Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.

Authors:  M Ohtsubo; A M Theodoras; J Schumacher; J M Roberts; M Pagano
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

9.  Different roles for cyclins D1 and E in regulation of the G1-to-S transition.

Authors:  D Resnitzky; S I Reed
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

Review 10.  Mammalian G1 cyclins.

Authors:  G F Draetta
Journal:  Curr Opin Cell Biol       Date:  1994-12       Impact factor: 8.382

View more
  75 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

Review 3.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

Review 4.  Comparative pathogenesis of epsilonretroviruses.

Authors:  Donald Holzschu; Lorie A Lapierre; Michael D Lairmore
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform.

Authors:  Sang Soo Kim; Liu Cao; Sung-Chul Lim; Cuiling Li; Rui-Hong Wang; Xiaoling Xu; Richard Bachelier; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

6.  Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism.

Authors:  J Langenfeld; H Kiyokawa; D Sekula; J Boyle; E Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

7.  The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles.

Authors:  Reiko Honda; Edward D Lowe; Elena Dubinina; Vicky Skamnaki; Atlanta Cook; Nick R Brown; Louise N Johnson
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

Review 8.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

9.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

Review 10.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.